Curis Inc (CRIS)
NASDAQ:CRIS
Top Page
Curis
(NASDAQ:CRIS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.52
▼(-3.33% Downside)
Action:ReiteratedDate:03/25/26
The score is weighed down primarily by persistent operating losses, ongoing cash burn, and balance-sheet/equity instability typical of a high-financing-risk biotech. Technicals also reflect a clear downtrend (below key moving averages with negative MACD). Offsetting factors are mixed but include improved expense discipline and guided runway into 2027, plus supportive financing/listing developments—tempered by dilution risk, contingent funding, and the lack of recurring revenue following the Erivedge sale.
Positive Factors
Regulatory path for PCNSL
A defined registrational pathway with FDA and EMA alignment for a single‑arm ORR endpoint materially reduces regulatory uncertainty. For a rare indication like PCNSL, this can shorten time to approval and create a clearer commercialization timeline if trial results meet endpoints, strengthening long-term strategic value.
Negative Factors
Loss of recurring revenue
The sale of Erivedge eliminated Curis's legacy revenue stream, removing recurring commercial cash inflows. Without product revenues, the company must rely on milestone payments, partnerships or financing to sustain operations, increasing long‑term execution and liquidity risk absent successful clinical or licensing outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory path for PCNSL
A defined registrational pathway with FDA and EMA alignment for a single‑arm ORR endpoint materially reduces regulatory uncertainty. For a rare indication like PCNSL, this can shorten time to approval and create a clearer commercialization timeline if trial results meet endpoints, strengthening long-term strategic value.
Read all positive factors
Curis (CRIS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.82M
Dividend YieldN/A
Average Volume (3M)68.01K
Price to Earnings (P/E)―
Beta (1Y)2.89
Revenue Growth13.56%
EPS Growth52.92%
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.23
Shares Outstanding39,978,690
10 Day Avg. Volume74,344
30 Day Avg. Volume68,010
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)23.79
Price to Sales (P/S)13.76
P/FCF Ratio-4.78
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue0.40
Enterprise Value/Gross Profit0.40
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$11.00Price Target Upside1937.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.73
Revenue Forecast (FY)$12.52M
Curis Business Overview & Revenue Model
Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidat...
How the Company Makes Money
Curis has historically generated revenue primarily through collaboration-related payments (such as upfront fees, milestone payments, and reimbursement for research and development services) and, where applicable, royalties on partnered products. T...
Curis Earnings Call Summary
Earnings Call Date:Mar 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call contained several meaningful clinical and financial positives: a clear registrational pathway and regulatory alignment for PCNSL, encouraging AML MRD conversion data (62.5% in evaluable patients), initiation of a CLL proof-of-concept study with expected ASH data, and sharply reduced operating expenses with an improved full-year net loss. Offsetting these positives are the end of legacy revenue, the Q4 profit being driven by a one-time non-cash gain rather than recurring operations, slow enrollment risk for the rare PCNSL population, and contingent financing tied to clinical milestones. On balance the updates reflect solid clinical progress and a strengthened near-term financial position, but with key operational and revenue risks that investors should monitor.Positive Updates
Registrational Pathway for PCNSL with Regulatory Support
TakeAim Lymphoma (PCNSL) is a single-arm registrational study with an ORR endpoint; company reports collaborative discussions with FDA and EMA and expects the study to support accelerated submissions in the US and Europe. Enrollment is on track with an estimated 12–18 months to full enrollment and potential filing in 2027 after ~6 months of follow-up.
Negative Updates
No Meaningful Revenue Going Forward
Revenue effectively ended in November 2025 following the Erivedge sale; management expects no meaningful revenue for 2026 and beyond, eliminating that legacy cash stream.
Read all updates
Q4-2025 Updates
Positive
Negative
Registrational Pathway for PCNSL with Regulatory Support
TakeAim Lymphoma (PCNSL) is a single-arm registrational study with an ORR endpoint; company reports collaborative discussions with FDA and EMA and expects the study to support accelerated submissions in the US and Europe. Enrollment is on track with an estimated 12–18 months to full enrollment and potential filing in 2027 after ~6 months of follow-up.
Read all positive updates
Company Guidance
Curis gave clinical and financial guidance focused on advancing its emavusertib programs and conserving cash: clinically, the single‑arm TakeAim Lymphoma registrational study (ORR endpoint) in PCNSL is “on track” with enrollment described as roughly one to two patients per month and management reiterating a 12–18 month estimate to full enrollment with potential to file after ~6 months of follow‑up (targeting a 2027 filing window) and expectations from FDA and EMA that the study could support accelerated submissions in the U.S. and Europe; the proof‑of‑concept CLL study is activating sites in the U.S. and Europe with initial data expected at ASH in December and dosing the 5th CLL patient would trigger exercise of Series B PIPE warrants; AML triplet data showed 5 of 8 evaluable patients achieved MRD conversion in the first two cohorts (emavusertib given 7 or 14 days in a 28‑day cycle). Financially, Q4 2025 net income was $19.4M ($1.23/share) versus a Q4 2024 net loss of $9.6M ($1.25/share); full‑year 2025 net loss was $7.6M ($0.58/share) versus $43.4M ($6.88/share) in 2024; R&D was $5.8M in Q4 and $28.3M for FY2025 (vs. $9.0M Q4 and $38.6M FY2024); G&A was $2.9M in Q4 and $14.0M for FY2025 (vs. $3.4M Q4 and $16.8M FY2024); results included a $27.2M one‑time non‑cash gain from the Erivedge sale, revenue effectively ended November 2025, and cash and cash equivalents as of 12/31/2025 plus $20.2M received in January 2026 and up to an additional $20.2M upon warrant exercise are expected to fund operations into 2027.Curis Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Gross Profit | 9.40M | 10.81M | 9.81M | 9.90M | 10.12M |
| EBITDA | -32.73M | -42.57M | -45.14M | -51.67M | -40.81M |
| Net Income | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
Balance Sheet | |||||
| Total Assets | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 20.00M | 56.33M | 85.62M | 115.88M |
| Total Debt | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Total Liabilities | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Stockholders Equity | 5.46M | -6.00M | 19.67M | 46.55M | 90.71M |
Cash Flow | |||||
| Free Cash Flow | -27.20M | -39.56M | -38.43M | -54.75M | -37.62M |
| Operating Cash Flow | -27.20M | -39.56M | -38.43M | -54.34M | -37.62M |
| Investing Cash Flow | 2.50M | 29.44M | 37.79M | 33.02M | -47.90M |
| Financing Cash Flow | 9.77M | 3.44M | 7.58M | 867.00K | -4.17M |
Curis Technical Analysis
Negative
0.54
Price Trends
0.89
Negative
1.00
Negative
1.35
Negative
Market Momentum
-0.12
Positive
28.03
Positive
19.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.89, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 28.03 is Positive, neither overbought nor oversold. The STOCH value of 19.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRIS.
Curis Risk Analysis
Curis disclosed 61 risk factors in its most recent earnings report. Curis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Curis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $43.48M | -3.44 | -16.25% | ― | 12.71% | 79.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $5.46M | -1.08 | -226.28% | 10.27% | 9.46% | 96.85% | |
46 Neutral | $21.82M | -17.14 | 354.21% | ― | 13.56% | 52.92% | |
46 Neutral | $12.97M | -1.17 | ― | ― | ― | 79.31% | |
43 Neutral | $4.35M | -1.58 | -79.47% | ― | -99.97% | 35.59% |
* Healthcare Sector Average
CRIS
Curis
0.55
-0.67
-55.33%
BGMS
Bio Green Med Solution
0.99
-53.49
-98.18%
MBRX
Moleculin Biotech
2.43
-16.70
-87.30%
PULM
Pulmatrix
1.19
-4.47
-78.98%
RLYB
Rallybio
8.22
6.22
311.00%
Curis Corporate Events
Business Operations and StrategyShareholder Meetings
Curis Shareholders Approve Major Equity and Charter Changes
Positive
Mar 17, 2026
On March 17, 2026, Curis, Inc. held a virtual special meeting at which stockholders approved a new 2026 Incentive Plan, authorizing millions of additional shares for equity awards and allowing annual share pool increases through 2036, including up...
Delistings and Listing ChangesRegulatory Filings and Compliance
Curis Regains Nasdaq Compliance, Remains Under Monitoring Period
Positive
Feb 9, 2026
On February 3, 2026, Curis, Inc. announced that it had received written notice from Nasdaq that the company had regained compliance with Nasdaq Listing Rule 5550(b)(2), restoring full compliance with the conditions previously set by a Nasdaq Heari...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Curis Announces PIPE Financing and Strategic Capital Strengthening
Positive
Jan 8, 2026
On January 7, 2026, Curis entered into a private placement securities purchase agreement with healthcare-focused institutional investors and company insiders for a PIPE financing structured around 20,195 shares of Series B convertible non-redeemab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.